Apyx medical corporation announces two peer-reviewed publications on the use of renuvion in abdominal body contouring procedures

Two studies report favorable clinical outcomes and safety data for renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin rapid weight loss due to glp-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin clearwater, fla., april 29, 2025 (globe newswire) -- apyx medical corporation (nasdaq: apyx) (“apyx medical” or the “company”), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of renuvion during body contouring procedures that also included lipoabdominoplasty1.
APYX Ratings Summary
APYX Quant Ranking